Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 22

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 22
---
 the proxy statement/prospectus. Kadimastem’s actual results may differ materially from those expressed in, or implied by, those forward -looking statements. See “Cautionary Note Regarding Forward -Looking Statements” in the proxy statement/prospectus. Overview Kadimastem is a clinical stage biotechnology company, with a unique platform for cell therapy that enables the production of off -the-shelfcell -basedproducts for the treatment of unmet medical needs. Kadimastem operates in the field of development of cell therapy, regenerative medicine, for the treatment of, among others, amyotrophic lateral sclerosis, or ALS, an incurable disease, for which Kadimastem received an orphan drug designation status from the U.S. Food and Drug Administration, or FDA, as well as cell therapy in the field of regenerative medicine for the treatment of diabetes, a disease that affects hundreds of millions of people worldwide, and its product has the potential to provide a cure for the disease. Kadimastem intends to be a leading company in the field of regenerative medicine products for the treatment of neurodegenerative diseases and a cure for diabetes. Kadimastem is developing revolutionary regenerative therapies based on stem cells -derivedtherapeutic cells, moving away from the traditional curative therapies. The technology has been developed as a platform enabling the manufacturing of islet -likeendocrine cells and glia restricted progenitors thus having potential applications for diabetes, and for neurodegenerative diseases such as ALS. The therapy is scalable and industrialized, to be commercialized as a stable “off the shelf” product and reduce the cost of treatments. For this, Kadimastem uses pluripotent cells (e.g. embryonic stem cells — hESCs) that have a unique ability to multiply infinitely without losing their “naivety” and to be able to become any cell type. The cell therapy products manufactured under Good Manufacturing Practices, or GMP guidelines (similar to traditional therapeutics) in order to reach optimal clinical results. Kadimastem developed a new process to differentiate the cells in the lab to their mature phenotype, before their implantation to the patient, unlike other technologies which transplant immature precursor cells. Thus, Kadimastem believes that its process will markedly enhance the efficiency of the treatment. Kadimastem implements a technological platform that uses pluripotent stem cells, or PSCs either embryonic stem cells and/or induced pluripotent stem cells for the development and production of various